Cyclin e amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients

Elizabeth Ann Mittendorf; K. Keyomarsi; K. K. Hunt

doi:10.1016/j.breastdis.2011.06.033

Cyclin e amplification/overexpression is a mechanism of trastuzumab resistance in HER2⁺ breast cancer patients

Elizabeth Ann Mittendorf, K. Keyomarsi, K. K. Hunt

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	266-267
Number of pages	2
Journal	Breast Diseases
Volume	22
Issue number	3
DOIs	https://doi.org/10.1016/j.breastdis.2011.06.033
State	Published - 2011

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1016/j.breastdis.2011.06.033

Cite this

@article{d204f163c50249de951eff670caab077,

title = "Cyclin e amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients",

author = "Mittendorf, {Elizabeth Ann} and K. Keyomarsi and Hunt, {K. K.}",

year = "2011",

doi = "10.1016/j.breastdis.2011.06.033",

language = "English (US)",

volume = "22",

pages = "266--267",

journal = "Breast Diseases",

issn = "1043-321X",

publisher = "Academic Press Inc.",

number = "3",

}

TY - JOUR

T1 - Cyclin e amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients

AU - Mittendorf, Elizabeth Ann

AU - Keyomarsi, K.

AU - Hunt, K. K.

PY - 2011

Y1 - 2011

UR - http://www.scopus.com/inward/record.url?scp=80052053190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052053190&partnerID=8YFLogxK

U2 - 10.1016/j.breastdis.2011.06.033

DO - 10.1016/j.breastdis.2011.06.033

M3 - Comment/debate

AN - SCOPUS:80052053190

SN - 1043-321X

VL - 22

SP - 266

EP - 267

JO - Breast Diseases

JF - Breast Diseases

IS - 3

ER -

Cyclin e amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this

Cyclin e amplification/overexpression is a mechanism of trastuzumab resistance in HER2⁺ breast cancer patients